Web of Pharma • Pharmaceutical Quality & Validation

CQV in Pharmaceuticals: Commissioning, Qualification and Validation

A complete, risk-based guide to the CQV lifecycle: how engineering commissioning, GMP qualification and process validation work together to bring pharmaceutical facilities, utilities, equipment and manufacturing processes into a controlled state.

GMP lifecycle Facilities • Utilities • Equipment Risk-based strategy IQ • OQ • PQ • PPQ

Quick answer: CQV means commissioning, qualification and validation. It is an integrated lifecycle approach used to show that pharmaceutical facilities, utilities, equipment, systems and processes are designed, installed and operated in a way that supports their intended GMP use and consistently protects product quality. Commissioning verifies engineering completion and function; qualification documents that facilities, utilities and equipment are fit for purpose; validation demonstrates that processes or methods achieve their intended results reproducibly. The work should be planned from intended use and risk, traced to approved requirements, supported by reliable records, reviewed by Quality, and maintained through change control and continued verification.

In this guide

1. What CQV means
2. Commissioning, qualification and validation compared
3. GMP and regulatory framework
4. CQV lifecycle: step by step
5. Risk-based scope and system impact
6. Documentation and traceability
7. Release, handover and continued control
8. Practical example
9. CQV readiness checklist
10. Common CQV gaps
11. Frequently asked questions

What Does CQV Mean in Pharmaceuticals?

CQV in pharmaceuticals is the coordinated set of planning, engineering, qualification and validation activities that provides documented assurance that a facility, utility, equipment item, computerized function or manufacturing process is suitable for its intended use. The letters stand for commissioning, qualification and validation. Companies often manage these activities through a single project plan because design, construction, equipment readiness and process readiness depend on one another.

CQV is an industry lifecycle term rather than the name of one universal regulation or one mandatory document sequence. Applicable requirements come from the markets in which a product is made or supplied, relevant GMP regulations and guidance, the product and process risks, and the manufacturer’s pharmaceutical quality system. A robust program connects engineering decisions to the quality requirements they are meant to protect.

For a new facility, CQV may span room and utility design, equipment procurement, construction verification, supplier testing, installation checks, functional challenge tests, process validation and operational handover. For a single replacement mixer or packaging line, the effort may be much narrower. In both cases, the manufacturer must define intended use, identify risks, set appropriate acceptance criteria and keep controlled records under cGMP.

Useful distinction: CQV is the coordinated program. Commissioning is primarily engineering verification; qualification focuses on fitness for intended use of facilities, utilities, equipment and systems; validation demonstrates that a process, cleaning procedure or method can achieve its intended outcome consistently.

Commissioning, Qualification and Validation Compared

These activities overlap in project timing, but each answers a different question. Keeping the objectives clear prevents both unnecessary duplicate testing and premature GMP release.

CQV element	Main question	Typical evidence	Example output
Commissioning	Was the system constructed, installed and started up according to its engineering design?	Construction checks, vendor start-up records, loop checks, balancing, functional testing, punch lists and turnover records.	Commissioning report and engineering handover package.
Qualification	Is the facility, utility, equipment or system suitable for its defined GMP intended use?	Approved requirements and risk assessment; design review; installation and operational evidence; performance testing; deviation closure.	Approved qualification report and authorized release decision.
Validation	Does the process, cleaning method or other defined operation achieve its intended result reproducibly?	Scientific rationale, approved protocol, defined operating conditions, sampling/testing data, acceptance criteria and ongoing monitoring.	Process performance qualification (PPQ), cleaning validation or method validation report.

A commissioning functional test may also satisfy a qualification test objective. That is acceptable only when a documented assessment confirms that the test is relevant, traceable, technically sound, performed on the final applicable configuration and reviewed against approved GMP acceptance criteria. PIC/S PI 006-4 specifically allows justified use of FAT and SAT testing to reduce the scope of IQ and OQ; it does not say that every vendor test automatically counts as qualification.

Do not confuse the terms “PQ” and “PPQ.” Equipment or system PQ commonly means performance qualification. FDA uses “process qualification” for Stage 2 of its process-validation lifecycle and “process performance qualification” (PPQ) for the manufacturing-process demonstration. A protocol should spell out the activity so the reader can tell which meaning applies.

GMP and Regulatory Framework for CQV

Regulators generally require suitable facilities, equipment, controlled procedures, documented evidence and a reproducible manufacturing process. The organization selects a scientifically sound approach that meets the rules applicable to its products and markets. Guidance documents help explain accepted approaches, but their legal status and implementation depend on the issuing authority and local adoption.

FDA requirements and process-validation guidance

For U.S. finished pharmaceuticals, 21 CFR Part 211 includes requirements for suitable premises and equipment, written procedures, equipment cleaning and maintenance, automated equipment controls, and quality-unit responsibilities. For example, §§ 211.63 and 211.65 address equipment design and construction; § 211.67 addresses cleaning and maintenance; § 211.68 addresses automatic, mechanical and electronic equipment; and § 211.100 addresses written production and process-control procedures. The site must apply the relevant requirements to each system’s actual intended use. See the Web of Pharma overview of 21 CFR regulations.

FDA’s process-validation guidance describes a lifecycle of process design, process qualification and continued process verification. Stage 2 includes two distinct elements: facility design and qualification of utilities and equipment, followed by process performance qualification. This makes an important point for CQV: a qualified facility and equipment are foundations for PPQ, but they do not by themselves prove that the manufacturing process is reproducible. FDA guidance is nonbinding; applicable statutes and regulations remain the enforceable requirements.

EU GMP Annex 15 and PIC/S PI 006-4

EU GMP Annex 15 covers qualification and validation principles and has been in operation since 1 October 2015. PIC/S PI 006-4, Recommendations on Qualification and Validation, is dated 1 October 2026 and supplements the qualification and validation principles in PIC/S and EU GMP Annex 15. PI 006-4 defines qualification as the evidence that facilities, supporting utilities, equipment and systems are suitable for intended use; it uses validation for process, cleaning and method validation. It also recognizes that appropriate science- or engineering-based approaches may use different terminology, provided the intended fitness-for-purpose evidence is achieved.

Under PI 006-4, the extent of qualification and validation should be identified and justified using product and process knowledge and quality risk management. The document expects lifecycle planning, appropriate Quality oversight, controlled deviations and attention to data integrity. Check the current local implementation and market-specific requirements before applying any guidance to a particular site.

For the engineering-to-GMP handover, see related guidance on Equipment Validation, HVAC Validation and Computerized System Validation.

CQV Lifecycle in Pharmaceutical Manufacturing: Step by Step

A lifecycle approach starts with business and user needs, then carries their quality-critical requirements through design, construction, testing, release and routine operation. The exact documents and order may differ by project and risk, but the decision trail should remain clear.

Phase	Purpose and typical activities	Key evidence or decision
1. Concept and scope	Define project boundaries, intended use, products/processes served, system interfaces, market requirements and project change control.	Approved scope, system boundary, preliminary impact assessment and CQV strategy.
2. Requirements and risk	Engage Quality, Engineering, Operations, Validation, Automation and users to define testable requirements; identify critical quality functions and failure modes.	Approved URS, risk assessment and traceability approach.
3. Design and supplier selection	Confirm that the selected design, materials, capacity, controls and operating ranges can meet approved requirements.	Design review or DQ, design specifications, drawings and supplier assessment.
4. Build and commissioning	Inspect construction and installation; complete start-up, instrument checks, balancing, control-loop testing and engineering functional tests.	FAT/SAT and commissioning evidence; resolved or risk-assessed punch-list items.
5. Qualification	Verify the installed system and its functions against intended use and GMP requirements. Use an appropriate IQ/OQ/PQ sequence or justified alternative.	Approved protocols, test results, traceability, deviations, reports and Quality decision.
6. Process and cleaning validation	Demonstrate process performance under defined commercial or routine conditions; validate cleaning where required by risk and the quality system.	Approved PPQ and cleaning-validation protocols/reports; justified sampling and acceptance criteria.
7. Release and operation	Transfer the asset to trained owners with approved procedures, maintenance, calibration, monitoring and escalation pathways.	Documented release for intended use and an effective state-maintenance plan.
8. Continued state of control	Manage changes, deviations, breakdowns, trends, periodic review and requalification when justified.	Current status, lifecycle records and evidence that controls remain effective.

Where IQ, OQ and PQ fit

Installation qualification (IQ) records that the system and its components are installed as approved and that relevant documentation, utilities and instruments are in place. Operational qualification (OQ) challenges functions, alarms, interlocks and operating ranges under defined conditions. Performance qualification (PQ) demonstrates performance in the operating context for which the system is intended, often with representative loads, materials, users or process conditions.

IQ/OQ/PQ are a familiar structure, not a substitute for thinking. A risk-based program may combine activities, use supplier evidence or adopt a different scientifically justified model. If stages are combined, the protocol should still make clear which requirements were tested, how pass/fail decisions were reached, what deviations occurred and who approved release.

For process validation, distinguish equipment readiness from manufacturing-process performance. FDA’s lifecycle places facility/equipment qualification and process performance qualification within Stage 2, followed by continued process verification. Read the related Process Validation guide for PPQ and ongoing verification.

Risk-Based Scope: What Should Be Included in CQV?

CQV scope should reflect the system’s function, complexity, novelty and possible effect on patient safety, product quality, contamination control, process consistency and regulated records. Risk assessment is used to prioritize effort and explain the extent of testing—not to remove controls without evidence or rationale.

System or activity	Potential GMP connection	Possible CQV focus
Manufacturing equipment	Product-contact materials, mixing, filling, dosing, sterilization or packaging accuracy.	Materials and design, installation, operating range, alarms, interlocks, cleaning, performance and interfaces.
Critical utilities	Water, clean steam, compressed gases or HVAC may directly or indirectly affect product or the manufacturing environment.	Design basis, construction, distribution, monitoring, alarms, sampling points, operating range and state-maintenance controls.
Facility and cleanroom	Room layout, pressure relationships, temperature, humidity and contamination-control strategy support the process.	Construction checks, airflow/HVAC qualification, environmental controls, room classification and operational conditions as applicable.
Automation and computerized functions	Control logic, recipes, alarms, electronic records, access or data transfer may affect a GMP decision or record.	System boundaries, interfaces, configuration, access, data flows, audit trail and software validation scope as appropriate.
Manufacturing process	Variability in process parameters can affect critical quality attributes and batch consistency.	Development knowledge, control strategy, PPQ protocol, sampling, acceptance criteria and continued process verification.
Cleaning process	Residues or microorganisms may carry over and affect the next product or process.	Worst-case rationale, equipment grouping, sampling recovery, analytical method suitability, limits and routine controls.

For example, an HVAC system that controls a critical manufacturing environment may require robust qualification and ongoing monitoring, while a non-GMP office comfort system may not belong in the same qualification scope. The decision should be based on documented system boundaries and impact assessment. See HVAC Validation in Pharmaceuticals for HVAC-specific tests.

For cleaning, process and computerized functions, create fit-for-purpose strategies rather than treating every activity as equipment testing. Related articles: Cleaning Validation and Computerized System Validation.

CQV Documentation, Traceability and Acceptance Criteria

Documentation should tell the story of how requirements were translated into design, how the design was verified, how risks were controlled, what was tested and why the final system was released. A reviewer should be able to follow a critical requirement from its source to an objective result and a clear disposition.

Core CQV records

• Validation Master Plan (VMP) or site strategy: Describes governance, scope, responsibilities, risk approach, document structure and lifecycle controls.
• Project CQV plan: Defines assets, boundaries, milestones, test strategy, owners, dependencies, hold points and release route.
• URS and design records: Capture intended use, measurable requirements, specifications, drawings, design decisions and design review.
• Risk and impact assessments: Explain system criticality, quality risks, failure controls and rationale for the extent of testing.
• Supplier and commissioning package: Includes FAT/SAT, inspection records, functional tests, instrument details and final turnover records.
• Qualification protocols and reports: Include approved criteria, executed results, data, deviations, traceability and an evidence-based conclusion.
• Validation protocols and reports: Cover applicable process, cleaning or analytical method validation and explain how the defined outcome is assessed.
• Operational readiness records: Approved SOPs, training, calibration, preventive maintenance, spare parts and system monitoring arrangements.
• Lifecycle records: Change controls, deviations, CAPA, periodic review, requalification decisions and status tracking.

Set acceptance criteria before execution

Each criterion should be objective, testable, technically justified and linked to a requirement, design specification, process need, risk control or applicable standard. State the test condition, measurement method, data to capture, tolerance or limit, and how exceptions will be handled. If an acceptance limit changes, manage it through formal change control and assess the impact; do not quietly adjust it after seeing results.

Maintain complete and attributable records, including original data, dates, equipment identifiers, software/configuration version where relevant, calibration status, observed results, retests and reviewer approvals. Follow ALCOA+ data-integrity principles and the site’s records policy. Any failed criterion or execution error needs a documented deviation assessment and appropriate investigation or CAPA where warranted.

GMP Release, Handover and Maintaining the Qualified State

Qualification or validation is not complete just because a protocol has been executed. Before GMP use, the responsible functions should review results, close or appropriately disposition deviations, confirm that residual risks are acceptable, and approve the report and release decision. The release record should identify the asset, its intended use, approved operating envelope, any restrictions and the required routine controls.

Operations and maintenance teams need usable documentation, training, calibration and preventive-maintenance schedules, cleaning instructions, spare parts and escalation routes. If the system includes software that controls a GMP function or produces regulated data, define its computerized-system scope and interfaces. CQV of the physical equipment alone does not complete software validation.

After release, keep the system in a controlled state through change control, maintenance, calibration, deviation management, trend review and periodic assessment. A significant change, repeated failure, relocation or utility modification may require additional qualification. The need and extent of requalification should be justified using documented impact and risk assessment rather than applying an arbitrary test repeat.

Process validation continues beyond initial PPQ. Continued process verification uses routine manufacturing information to confirm that the process remains in control and to identify drift or emerging variability. For linked governance, review CAPA, Computerized System Validation and the equipment lifecycle guide.

Practical CQV Example: New Purified Water System

Suppose a site installs a purified-water system that supplies manufacturing and cleaning operations. The CQV team first defines the intended uses and system boundary, including pretreatment, generation, storage, distribution, return loop, monitoring instruments and points of use. Quality, Engineering, Operations, Microbiology and Validation agree on the applicable requirements and assess risks such as microbial growth, material compatibility, temperature control, monitoring gaps and loss of circulation.

During design, the team reviews materials, capacities, sampling locations, instrument ranges, alarm strategy and access for maintenance. During construction and commissioning, it checks installation, weld documentation, slope or drainability where required, instrument loops, pump rotation, controls and flushing. Supplier FAT and site SAT results may be used where the test conditions and configuration are suitable and the evidence is complete.

Qualification then verifies the final installed system against approved requirements. IQ evidence addresses components, drawings, utilities and calibration. OQ challenges operating modes, alarms, interlocks and ranges. Performance testing samples representative points under defined operating conditions over a protocol-justified period. Validation of the water-use process, where required, is supported by the overall monitoring and control strategy. Site-specific chemical and microbiological limits, sampling frequency and duration must come from applicable requirements, system design and risk assessment—not from a generic article.

Before release, the site reviews results and deviations, approves water-system procedures, trains users, establishes sanitization, maintenance and monitoring controls, and documents who may release the system for the defined GMP use.

CQV Readiness Checklist for Pharmaceutical Projects

1. Set a clear boundary. Identify the facility, utility, equipment, software, process and interfaces included in the CQV scope.
2. Define intended use. State what the asset must do, which products or operations it supports and what it must not be used for.
3. Agree on governance. Assign Engineering, Operations, Quality, Validation, Automation, supplier and contractor responsibilities.
4. Approve testable requirements. Ensure the URS and design documents contain measurable, reviewable requirements.
5. Assess risk early. Link potential failures to product quality, patient safety, contamination, process control or data integrity.
6. Plan commissioning and qualification together. Identify which supplier or engineering tests may support GMP evidence and what gaps require qualification testing.
7. Define criteria before testing. Approve protocols, methods, instruments, acceptance criteria, sampling and deviation rules in advance.
8. Control evidence and data. Retain raw data, identify configuration and calibrated instruments, review calculations and preserve traceability.
9. Resolve deviations transparently. Investigate failures, assess impact, justify retests and approve corrective actions.
10. Confirm operational readiness. Approve SOPs, training, maintenance, cleaning, calibration and monitoring before release.
11. Authorize GMP use. Ensure the required report approvals and formal release are documented by authorized roles.
12. Maintain the lifecycle state. Apply change control, periodic review, continued process verification and risk-based requalification.

Common CQV Mistakes and How to Prevent Them

• Calling every project test “validation”: Label each activity by its objective so commissioning, qualification, process validation and software validation are not confused.
• Using a generic checklist without impact assessment: Tailor scope to system boundaries, intended use and documented quality risks.
• Assuming IQ/OQ/PQ is the only valid model: Use an approach that meets applicable requirements; justify combined or alternative verification structures clearly.
• Accepting vendor evidence without review: Check requirement traceability, test conditions, final configuration, raw data, calibration and deviation status.
• Repeating every test by default: Assess whether previous testing is relevant and robust before repeating; add tests where gaps remain.
• Confusing equipment PQ and process PPQ: State whether a protocol tests equipment performance or demonstrates reproducible manufacturing-process performance.
• Approving criteria after execution: Establish and approve acceptance criteria before testing; control changes through the quality system.
• Leaving punch-list items outside the GMP assessment: Evaluate open items for quality impact, assign owners and due dates, and document release restrictions or closure.
• Releasing before routine controls are ready: Ensure procedures, training, maintenance, calibration and monitoring are effective before operational handover.
• Treating qualification as a one-time event: Use change control and routine performance data to decide whether review, corrective action or requalification is needed.

Frequently Asked Questions About CQV in Pharmaceuticals

1. What does CQV stand for in pharmaceuticals?

CQV stands for commissioning, qualification and validation. It describes a coordinated lifecycle that brings facilities, utilities, equipment, systems and processes from requirements and design through testing, release and continued control.

2. What is the difference between commissioning and qualification?

Commissioning verifies engineering construction, installation and functional operation. Qualification documents that facilities, utilities, equipment or systems are suitable for their intended GMP use. Some commissioning evidence may be leveraged when it meets the qualification objective and is properly assessed.

3. What is the difference between qualification and validation?

In PIC/S PI 006-4 terminology, qualification covers facilities, supporting utilities, equipment and systems; validation covers processes, cleaning and analytical methods. Both use documented, risk-based evidence, but they demonstrate different things.

4. Is CQV required by FDA or EU GMP as a single named program?

CQV is commonly used as an industry umbrella term. Applicable GMP rules require suitable facilities and equipment, controlled procedures and validated processes, while specific guidance describes approaches. There is not one universally prescribed “CQV” document or sequence for every asset.

5. Are IQ, OQ and PQ always required as separate protocols?

They are a common qualification structure, but the appropriate approach depends on applicable requirements and the asset’s risk and complexity. Alternative or combined approaches may be used when scientifically justified and supported by clear evidence and approvals.

6. Can FAT and SAT replace IQ or OQ?

Not automatically. PIC/S PI 006-4 says FAT and SAT may reduce the required scope of IQ and OQ when justified. The site should evaluate test coverage, criteria, configuration, shipment effects, instruments, data completeness and remaining gaps.

7. What does FDA mean by Stage 2 process qualification?

FDA’s process-validation lifecycle defines Stage 2 as process qualification. It includes facility design and qualification of equipment and utilities, as well as process performance qualification (PPQ). Equipment qualification alone does not demonstrate reproducible process performance.

8. What should a CQV plan include?

A project CQV plan typically identifies intended use, system boundaries, applicable requirements, risk rationale, responsibilities, testing strategy, acceptance criteria, documents, hold points, deviations, change control, release approvals and lifecycle controls.

9. When can equipment be released for GMP use?

Release follows completion and review of required evidence, disposition of deviations and open items, confirmation that procedures and training are ready, and documented approval by authorized roles under the site quality system.

10. How is the qualified or validated state maintained?

Maintain the state through approved operation, cleaning, maintenance and calibration, personnel training, change control, deviation management, trend review, periodic review, continued process verification and risk-based requalification when needed.

Related Pharmaceutical Validation Guides

• Equipment Validation in Pharmaceuticals
• Process Validation in Pharmaceuticals
• Cleaning Validation in Pharmaceuticals
• HVAC Validation in Pharmaceuticals
• Computerized System Validation

Official References and Further Reading

• PIC/S PI 006-4: Recommendations on Qualification and Validation (dated 1 October 2026)
• European Commission: EudraLex Volume 4, including EU GMP Annex 15
• FDA: Process Validation—General Principles and Practices
• Electronic Code of Federal Regulations: 21 CFR Part 211

Educational information only. This article is not a substitute for current regulations, market-specific requirements, controlled site procedures or a product- and system-specific quality risk assessment. Confirm the applicable version and local adoption before use.